Wacker Chemie and MorphoSys have expanded their existing collaboration for the use of Wacker’s Esetec bacterial secretion technology. MorphoSys will now be able to use the technology for the production of antigen material in addition to the production of antibodies in both the early development of therapeutics and the production of diagnostic and research antibodies. The technology, together with MorphoSys’ production platforms, has the potential to offer advantages with the production of novel ...